EN DE
Watch Acer Medical Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Acer Medical Inc. (6857) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of Acer Medical Inc. stock TWD 58.71, price TWD 89.10, that is 34.1% below the price, quality 50 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN TW0006857006

AM Acer Medical Inc. logo Thin data Nov 16, 2026

Acer Medical Inc.

6857 · TWO

Expensive (fair value 34% below the price), but solid company.

Get notified free when this changes
Revenue last quarter +35% vs. a year ago. 
Quality 50/100 
Expensive Growth (revenue 5y +126.2 %/yr in TWD) 
Fair value 58.71 TWD · Overvalued 
Loss-making · -33.6% net margin (TTM) 
Negative free cash flow 
Trails peers (1/9) 
Narrow moat 12/100
Thin data 
Estimate⚠ Thinly traded
Watch Acer Medical Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

125.00 TWD 89.00 TWD Fair Value 58.71 TWD Dec 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

12‑month range 89.00 TWD – 125.00 TWD · fair‑value band 44.03 TWD – 73.38 TWD · the 89.10 TWD price screens above the 58.71 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Acer Medical in your weekly email

Every Wednesday you see whether Acer Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Acer Medical Inc. offers artificial intelligence, clinical data, and software for healthcare sector.

Show moreShow less

It offers VeriSee DR, an AI-assisted diagnostic software for diabetic retinopathy identification; VeriSee AMD, an AI-assisted screening software for age-related macular degeneration identification; and VeriOsteo OP, an AI-assisted screening software for bone mineral density abnormalities.

Acer Medical Inc. was founded in 2018 and is based in New Taipei City, Taiwan.

Stock analysis

Acer Medical Inc. (6857) currently trades at 89.10 TWD, while our estimate is 58.71 TWD, 34% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 44.03 TWD (bear) to 73.38 TWD (bull), the price of 89.10 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Acer Medical Inc. reported revenue of 60.1M TWD in FY2025 versus 9.6M TWD in FY2021, a compound +58.0%/yr. Reported net income was −29.7M TWD in FY2025.

Key figures

Market cap 1.4B TWD (≈ $41.1M) Micro · P/S ratio 20.2 · EPS (TTM) −1.56 TWD · Net margin −33.6% · Return on equity −14.1% · Return on assets (EBIT) −15.8% (5-year average) · Operating margin −25.8% · Revenue (TTM) 70.5M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 29% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −34%, 6857 screens richer than that median.

Fair Value

Bear 44.03 TWD Fair Value 58.71 TWD Bull 73.38 TWD
Price 89.10 TWD · Downside -34.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 50/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 9
How much profit the company makes from its sales and capital
Quality Growth 67
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 74
How calm the share price moves, does not count
Price momentum 34
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 5
Distance to the 52-week high, does not count
New shares 43
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+19.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+66.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+126.2%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,185.2% (2020) → −54.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6857 screens overvalued: fair value 34% below the price. Compare with Veeva Systems Inc →

Compare Acer Medical Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 140 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 50 · Below median
Fair Value upside −34.1% · Below median
Profitability
Return on assets −14.3% · Below median
Net margin (12 months) −33.6% · Bottom 25%
Operating margin (12 months) −25.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 34.6% · Top 25%

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/B 8.23× · Priciest 25%
P/S (12 months) 19.25× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)100 · sector 46
PAST (return on equity)0 · sector 3
HEALTH (low debt)0 · sector 98
DIVIDEND (yield)0 · sector 43

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Doximity, Inc DOCS $32.77 $36.67 +12% vs 6857
Veeva Systems Inc VEEV $299.28 $329.21 +10% vs 6857
HealthEquity, Inc HQY $104.58 $115.04 +10% vs 6857
Waystar Holding WAY $28.11 $29.10 +4% vs 6857
Tempus AI, Inc TEM $64.76 $52.58 −19% vs 6857
HeartFlow, Inc HTFL $46.86 $30.50 −35% vs 6857
Hinge Health, Inc HNGE $121.29 $51.25 −58% vs 6857
Pro Medicus Limited PME A$201.65 A$82.80 −59% vs 6857
BrightSpring Health Services, Inc BTSG $71.37 $25.72 −64% vs 6857
XtalPi Holdings 2228 HK$5.32 HK$1.53 −71% vs 6857

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Acer Medical Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Acer Medical Inc. Fair Value". https://www.fairvalue-calculator.com/stock/6857

Frequently asked questions

Is Acer Medical Inc. (6857) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is 58.71 TWD versus a price of 89.10 TWD, about 34% lower (overvalued).
What is the fair value of 6857?
Our estimate for Acer Medical Inc. is 58.71 TWD (as of Nov 16, 2026), built from audited fundamentals. The current price: 89.10 TWD.
What is the quality score of 6857?
Acer Medical Inc. has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Acer Medical Inc. (6857)?
Our calculated price target is the estimate of 58.71 TWD (as of Nov 16, 2026). Cautious scenario 44.03 TWD, optimistic scenario 73.38 TWD. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Acer Medical Inc. stock forecast for 2026?
Our estimate puts fair value at 58.71 TWD, about 34% lower versus a price of 89.10 TWD (overvalued). Cautious scenario 44.03 TWD, optimistic scenario 73.38 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Acer Medical Inc. (6857)?
Acer Medical Inc. reported trailing-twelve-month revenue of about 70.5M TWD (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of Acer Medical Inc. (6857)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Acer Medical Inc. it is 58.71 TWD per share (as of Nov 16, 2026), against a price of 89.10 TWD.
Is Acer Medical Inc. stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 6857 trades above its calculated fair value: price 89.10 TWD, fair value 58.71 TWD, a gap of about −34% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6857?
No. The price is what the market pays today (89.10 TWD); the fair value is what the company's own numbers justify (58.71 TWD). For Acer Medical Inc. the two are 30.39 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Acer Medical Inc. worth?
The market values Acer Medical Inc. at about 1.4B TWD (market capitalisation, as of Nov 16, 2026). Per share that is 89.10 TWD; our models calculate a fair value of 58.71 TWD per share.
What do the bullish and bearish scenarios say about 6857?
Our models span a range for Acer Medical Inc.: cautious scenario 44.03 TWD, base 58.71 TWD, optimistic 73.38 TWD per share (as of Nov 16, 2026, price 89.10 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Acer Medical Inc. (6857)?
Balance-sheet figures for Acer Medical Inc. (as of Nov 16, 2026): return on equity −14.1%. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is 6857 from its 52-week high?
Acer Medical Inc. trades at 89.10 TWD, about 29% below its 52-week high of 125.00 TWD and at the low of 89.00 TWD (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of 58.71 TWD is for.
Which stocks are comparable to Acer Medical Inc.?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Tempus AI, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Acer Medical Inc. stock attractive at the current price?
The data as of Nov 16, 2026: price 89.10 TWD, calculated fair value 58.71 TWD (−34%), Quality Score 50/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Acer Medical Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Acer Medical Inc. (6857)?
The closing price on Nov 17, 2026 was 89.10 TWD. Our estimate is 58.71 TWD, about 34% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Acer Medical Inc. right now?
The price sits above even our optimistic bull case (73.38 TWD). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Acer Medical Inc.

How large is the market capitalisation of Acer Medical Inc. (6857)?
The market capitalisation of Acer Medical Inc. is 1.4B TWD (≈ $41.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Acer Medical Inc. (6857)?
The price-to-sales ratio of Acer Medical Inc. is 20.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Acer Medical Inc. (6857)?
Earnings per share at Acer Medical Inc. are −1.56 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Acer Medical Inc. (6857)?
The net margin of Acer Medical Inc. is −33.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Acer Medical Inc. (6857)?
The return on equity (ROE) of Acer Medical Inc. is −14.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Acer Medical Inc. (6857)?
On an EBIT basis the return on assets of Acer Medical Inc. is −15.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Acer Medical Inc. (6857)?
The operating margin of Acer Medical Inc. is −25.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Acer Medical Inc. (6857)?
Revenue at Acer Medical Inc. is growing 34.6% versus a year earlier (3y avg +66.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Acer Medical Inc. (6857) generate?
The free cash flow of Acer Medical Inc. is −25.7M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Acer Medical Inc. (6857) hold?
Acer Medical Inc. holds more cash than debt, 203M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Acer Medical Inc. in the live analysis

One click puts Acer Medical Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.